Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Clinical Pharmacokinetics|March 27, 2013
Pharmacometric characterization of dabigatran hemodialysisKarl-Heinz Liesenfeld, Alexander Staab, Sebastian Härtter, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|November 16, 2020
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular DegenerationRamin Tadayoni, Laura Sararols, Georges Weissgerber, et al.
Seminars in Arthritis and Rheumatism|July 30, 2025
Current evidence on switching between biologic therapies for Still's disease: A systematic literature reviewLorenzo Dagna, Eugen Feist, Gerd Horneff, et al.
BMJ Open|December 18, 2012
Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research DatabaseSally Lee, Brigitta U Monz, Andreas Clemens, et al.
Thrombosis Journal|June 20, 2012
Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trialsNadia Rosencher, Herbert Noack, Martin Feuring, et al.
Thrombosis and Haemostasis|October 23, 2010
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilateNeil S Roskell, Gregory Y H Lip, Herbert Noack, et al.
Annals of Medicine|September 2, 2014
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?Andreas Clemens, Andreas Strack, Herbert Noack, et al.
Thrombosis Journal|November 28, 2015
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgeryChristian Wurnig, Andreas Clemens, Helmuth Rauscher, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 31, 2010
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombinWolfgang G Eisert, Norbert Hauel, Joachim Stangier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 6, 2016
Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical RecordsWlodzimierz M Kolaczynski, Matthew Hankins, Siew H Ong, et al.
Pageof 9